Evidence map›Paper›PMID 26288687›Full record

ArticleACS medicinal chemistry letters2015

Modulation of the Interaction between a Peptide Ligand and a G Protein-Coupled Receptor by Halogen Atoms.

Mònica Rosa, Gianluigi Caltabiano, Katy Barreto-Valer, Verónica Gonzalez-Nunez, José C Gómez-Tamayo, Ana Ardá, Jesús Jiménez-Barbero, Leonardo Pardo, Raquel E Rodríguez, Gemma Arsequell and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. The Meta-Position of PheMolecules (Basel, Switzerland) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Mònica RosaInstitut de Química Avançada de Catalunya (I.Q.A.C.-C.S.I.C.) , E-08034 Barcelona, Spain.
Gianluigi CaltabianoLaboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona , E-08193 Bellaterra, Barcelona, Spain.
Katy Barreto-ValerDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, Instituto de Neurociencias de Castilla y León (INCyL), University of Salamanca , 37008 Salamanca, Spain ; Institute of Biomedical Research of Salamanca (IBSAL) , E-37007 Salamanca, Spain.
Verónica Gonzalez-NunezDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, Instituto de Neurociencias de Castilla y León (INCyL), University of Salamanca , 37008 Salamanca, Spain ; Institute of Biomedical Research of Salamanca (IBSAL) , E-37007 Salamanca, Spain.
José C Gómez-TamayoLaboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona , E-08193 Bellaterra, Barcelona, Spain.
Ana ArdáCIC bioGUNE, Bizkaia Technological Park , 48160 Derio, Spain ; Ikerbasque, Basque Foundation for Science , E-48013 Bilbao, Spain.
Jesús Jiménez-BarberoCIC bioGUNE, Bizkaia Technological Park , 48160 Derio, Spain ; Ikerbasque, Basque Foundation for Science , E-48013 Bilbao, Spain.
Leonardo PardoLaboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona , E-08193 Bellaterra, Barcelona, Spain.
Raquel E RodríguezDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, Instituto de Neurociencias de Castilla y León (INCyL), University of Salamanca , 37008 Salamanca, Spain ; Institute of Biomedical Research of Salamanca (IBSAL) , E-37007 Salamanca, Spain.
Gemma ArsequellInstitut de Química Avançada de Catalunya (I.Q.A.C.-C.S.I.C.) , E-08034 Barcelona, Spain.
Gregorio ValenciaInstitut de Química Avançada de Catalunya (I.Q.A.C.-C.S.I.C.) , E-08034 Barcelona, Spain.
Universitat Autònoma de Barcelona · ESUniversidad de Salamanca · ESCIC bioGUNE · ESIkerbasque · ESInstituto de Investigación Biomédica de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systematic halogenation of two native opioid peptides has shown that halogen atoms can modulate peptide-receptor interactions in different manners. First, halogens may produce a steric hindrance that reduces the binding of the peptide to the receptor. Second, chlorine, bromine, or iodine may improve peptide binding if their positive σ-hole forms a halogen bond interaction with negatively charged atoms of the protein. Lastly, the negative electrostatic potential of fluorine can interact with positively charged atoms of the protein to improve peptide binding.

Indexed as

drug designendomorphin-1G protein-coupled receptorshalogenated peptidesHalogen bondLeu-enkephalinneuropeptidesopioid receptors

Identifiers

PMID26288687
PMCPMC4538429
OpenAlexW1181321622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.